HomeMarket NewsDisappointing Performance: Armata Pharmaceuticals Falls Short on EPS, Surpasses Revenue Beyond Expectations...

Disappointing Performance: Armata Pharmaceuticals Falls Short on EPS, Surpasses Revenue Beyond Expectations in Q4 2023

Actionable Trade Ideas

always free

The Quarter in Review

Armata Pharmaceuticals (NYSEMKT:ARMP) has recently unveiled their financial results for the final quarter of 2023.

  • The company reported an earnings per share of -55 cents, missing the mark set by analysts at -35 cents.
  • On the revenue front, Armata Pharmaceuticals posted $1.53 million, exceeding analyst predictions by a staggering 77.67% ($860,000 estimate).

Automated Data at Work

InvestorPlace Earnings utilizes innovative data from TradeSmith to deliver real-time updates on quarterly earnings reports. Bringing to light pivotal insights like EPS and revenue figures, as well as a comparison to analyst projections. These reports are swift in their delivery, allowing our readers to stay informed amidst the ever-evolving financial landscape.

Closing Notes


View the original article on InvestorPlace Media, available at: https://investorplace.com/earning-results/2024/03/armp-stock-earnings-armata-pharmaceuticals-for-q4-of-2023/.

©2024 InvestorPlace Media, LLC

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.